Renovascular protective effects of erythropoietin in patients with chronic kidney disease

Internal Medicine

Volumn 50, Issue 18, 2011, Pages 1929-1934

  Fujiwara, Nobuharu ^a,b   Nakamura, Tsukasa ^a,b   Sato, Eiichi ^b   Kawagoe, Yasuhiro ^b   Hikichi, Yutaka ^a   Ueda, Yoshihiko ^c   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

^b Shinmatsudo Central General Hospital   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

CKD; Drug; Erythropoietin

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATININE; FATTY ACID BINDING PROTEIN; HEMOGLOBIN; N(G),N(G) DIMETHYLARGININE; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; ADULT; ANEMIA; ANTHROPOMETRIC PARAMETERS; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL PARAMETERS; BRACHIAL ANKLE PULSE WAVE VELOCITY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE MARKER; FEMALE; FLUID RETENTION; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART THORAX INDEX; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFERIOR CAVA VEIN; INFERIOR VENA CAVA DIMENSION; MALE; OXIDATIVE STRESS; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA;

ACUTE KIDNEY INJURY; AGED; ARGININE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR SYSTEM; CAROTID INTIMA-MEDIA THICKNESS; DEOXYGUANOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FATTY ACID-BINDING PROTEINS; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 80052865410     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5145     Document Type: Article

References (35)

1. Toyeux-Faure M. Cellular protection by erythropoietin: New therapeutic implications? J Pharmacol Exp Therapy 323: 759-762, 2007.
2. Gluhovschi G, Gluhovschi C, Bob F, et al. Multiorgan-protective actions of blockers of the renin-angiotensin system, statins and erythropoietin: common pleiotropic effects in reno-, cardio-and neuroprotection. Acta Clin Belg 63: 152-169, 2008.
3. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterolindependent manner. Pharmacol Res 61: 58-61, 2010.
4. Tanaka T, Doi K, Maeda-Mamiya R, et al. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. Am J Pathol 174: 1203-1211, 2009.
5. Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 333: 321-326, 2007.
6. Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 60: 525-528, 2009.
7. Kasap B, Soylu A, Kuralay F, et al. Protective effect of EPO on oxidative renal injury in rats with cyclosporine nephrotoxicity. Pediatr Nephrol 23: 1991-1999, 2008.
8. Bi B, Guo J, Marlier A, Lin SR, Cantley LG. Erythropoietin expands a stromal cell population that can mediate renoprotection. Am J Physiol Renal Physiol 295: F1017-F1021, 2008.
9. Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 45: 494-501, 2005.
10. Preston E, Ellis MR, Kulinskaya E, Davies AH, Brown A. Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD. Am J Kidney Dis 46: 856-862, 2005.
11. Ueda S, Yamagishi S, Matsumoto Y, et al. Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD). Life Sci 84: 853-856, 2009.
12. Kielstein JT, Fliser D. The past, presence and future of ADMA in nephrology. Nephrol Ther 3: 47-54, 2007.
13. Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK. Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol 3: 1644-1651, 2008.
14. Belov VV, Il'icheva OE. The role of brain natriuretic peptide in diagnosis of diastolic myocardial dysfunction in patients with predialysis chronic kidney disease. Kardiologiia 47: 10-13, 2007.
15. Goto S, Yoshida K, Kita T, Fujii H, Fukagawa M. Uremic toxins and oral adsorbents. Ther Apher Dial 15: 132-134, 2011.
16. Ayus JC, Go AS, Valderrabapo F, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int 68: 788-795, 2005.
17. Imai E, Horio M, Nitta K, et al. Modification of the modification of Diet in Renal Disease (MDRD) study equation for Japan. Am J Kidney Dis 50: 927-937, 2007.
18. Kamijo A, Kimura K, Sugaya T, et al. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 143: 23-30, 2004.
19. Saito S, Yamauchi H, Hasui Y, Kurashige J, Ochi H, Yoshida K. Quantitative determination of urinary 8-hydroxyguanosine (8-OHdG) by using ELISA. Res Commun Mol Pathol Pharmacol 107: 39-44, 2000.
20. Ueda S, Kato S, Matsuoka H, et al. Regulation of cytokineinduced nitric oxide synthesis by asymmetric dimethylarginine. Cir Res 92: 226-233, 2003.
21. Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 17: 2176-2183, 2006.
22. Nakamura T, Inoue T, Suzuki T, Ueda Y, Koide H, Node K. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res 31: 841-850, 2008.
23. Nakamura T, Suzuki T, Kawagoe Y, Koide H. Polymyxin Bimmobilized fiber hemoperfusion attenuates increased plasma atrial natriuretic peptide and brain natriuretic levels in patients with septic shock. ASAIO J 54: 210-213, 2008.
24. Shibazaki K, Kimura K, Okada Y, et al. Plasma brain natriuretic peptide as an independent predictor of in-hospital mortality after acute ischemic stroke. Intern Med 48: 1601-1606, 2009.
25. Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 18: 15-20, 2009.
26. Srisawat N, Manotham K, Eiam-Ong S, Katavetin P, Praditpornsilpa K, Eiam-Ong S. Erythropoietin and its non-erythropoietic derivative: Do they ameliorate renal tubulointerstitial injury in ureteral obstruction?. Int J Urol 15: 1011-1017, 2008.
27. Breggia AC, Wojchowski DM, Himmelfarb J. JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells. Am J Physiol Renal Physiol 295: F1689-F1695, 2008.
28. Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M. Antioxidative effects of erythropoietic. Kidney Int Suppl 107: S10-S15, 2007.
29. Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 11: 115-121, 2007.
30. Sharma M, Zhou Z, Miura H, et al. ADMA injures the glomerular filtration barrier: role of nitric oxide and superoxide. Am J Physiol Renal Physiol 296: F1386-F1395, 2009.
31. Furuki K, Adachi H, Matsuoka H. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis 191: 206-210, 2007.
32. Zhang L, Zhao F, Yang Y, et al. Association between carotid artery intima-media thickness and early-stage CKD in a Chinese population. Am J Kidney Dis 49: 786-792, 2007.
33. Pawiak K, Pawiak D, Mysliwiec M. Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patients. Am J Nephrol 26: 497-502, 2006.
34. Hirashiki A, Murohara T. The impact of pulse wave velocity in a Japanese population with metabolic syndrome. Hypertens Res 32: 1045-1046, 2009.
35. Dhar S, Pressman GS, Subramanian S, et al. Natriuretic peptides and heart failure in the patient with chronic kidney disease: A review of current evidence. Postgrad Med J 85: 299-302, 2009.